240 related articles for article (PubMed ID: 30762670)
81. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
[TBL] [Abstract][Full Text] [Related]
82. Update on intravesical agents for non-muscle-invasive bladder cancer.
Shariat SF; Chade DC; Karakiewicz PI; Scherr DS; Dalbagni G
Immunotherapy; 2010 May; 2(3):381-92. PubMed ID: 20635902
[TBL] [Abstract][Full Text] [Related]
83. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
84. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
85. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
86. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
87. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations.
Klaassen Z; Kamat AM; Kassouf W; Gontero P; Villavicencio H; Bellmunt J; van Rhijn BWG; Hartmann A; Catto JWF; Kulkarni GS
Eur Urol; 2018 Nov; 74(5):597-608. PubMed ID: 30017405
[TBL] [Abstract][Full Text] [Related]
88. Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guérin.
Morales A; Herr H; Steinberg G; Given R; Cohen Z; Amrhein J; Kamat AM
J Urol; 2015 Apr; 193(4):1135-43. PubMed ID: 25286009
[TBL] [Abstract][Full Text] [Related]
89. [ BCG-immunotherapy and bladder cancer].
Rischmann P
Prog Urol; 2008 May; 18 Suppl 5():S93. PubMed ID: 18585633
[No Abstract] [Full Text] [Related]
90. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.
Zhang GK; Uke ET; Sharer WC; Borkon WD; Bernstein SM
J Urol; 1996 Jun; 155(6):1907-9. PubMed ID: 8618284
[TBL] [Abstract][Full Text] [Related]
91. Current perspectives in bladder cancer management.
Griffiths TR;
Int J Clin Pract; 2013 May; 67(5):435-48. PubMed ID: 23137019
[TBL] [Abstract][Full Text] [Related]
92. Bacillus Calmette-Guerin (BCG) balanitis as a complication of intravesical BCG immunotherapy: a case report.
Erol A; Ozgür S; Tahtali N; Akbay E; Dalva I; Cetin S
Int Urol Nephrol; 1995; 27(3):307-10. PubMed ID: 7591595
[No Abstract] [Full Text] [Related]
93. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
[TBL] [Abstract][Full Text] [Related]
94. Re: Sequential Intravesical Gemcitabine and Docetaxel for Bacillus Calmette-Guérin-naïve High-risk Nonmuscle-invasive Bladder Cancer.
Kavoussi M; Nasrallah AA; Williams SB
Eur Urol; 2022 Dec; 82(6):659. PubMed ID: 36089530
[No Abstract] [Full Text] [Related]
95. Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Velaer KN; Steinberg RL; Thomas LJ; O'Donnell MA; Nepple KG
Curr Urol Rep; 2016 May; 17(5):38. PubMed ID: 26968418
[TBL] [Abstract][Full Text] [Related]
96. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
Gallagher BL; Joudi FN; Maymí JL; O'Donnell MA
Urology; 2008 Feb; 71(2):297-301. PubMed ID: 18308107
[TBL] [Abstract][Full Text] [Related]
97. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].
Leucht K; Foller S; Grimm MO
Urologe A; 2021 Nov; 60(11):1400-1408. PubMed ID: 34709440
[TBL] [Abstract][Full Text] [Related]
98. Treatment of non muscle invasive bladder tumor related to the problem of bacillus Calmette-Guerin availability. Consensus of a Spanish expert's panel. Spanish Association of Urology.
Fernández-Gómez JM; Carballido-Rodríguez J; Cozar-Olmo JM; Palou-Redorta J; Solsona-Narbón E; Unda-Urzaiz JM;
Actas Urol Esp; 2013; 37(7):387-94. PubMed ID: 23773824
[TBL] [Abstract][Full Text] [Related]
99. Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.
Ozbakkaloglu B; Tünger O; Sürücüoglu S; Lekili M; Kandiloglu AR
Int Urol Nephrol; 1999; 31(1):49-53. PubMed ID: 10408303
[TBL] [Abstract][Full Text] [Related]
100. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy?
Loertzer H; Brake M; Horsch R; Keller H
Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
